Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
6.65
+2.44 (57.96%)
At close: Aug 14, 2026, 4:00 PM EDT
6.52
-0.13 (-1.97%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Capricor Therapeutics Employees
Capricor Therapeutics had 231 employees as of December 31, 2025. The number of employees increased by 71 or 44.38% compared to the previous year.
Employees
231
Change (1Y)
71
Growth (1Y)
44.38%
Revenue / Employee
n/a
Profits / Employee
-$560,245
Market Cap
386.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 231 | 71 | 44.38% | 231 | 0 |
| Dec 31, 2024 | 160 | 58 | 56.86% | 160 | 0 |
| Dec 31, 2023 | 102 | 28 | 37.84% | 101 | 1 |
| Dec 31, 2022 | 74 | 26 | 54.17% | 74 | 0 |
| Dec 31, 2021 | 48 | 22 | 84.62% | 48 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| Rocket Pharmaceuticals | 202 |
| Enanta Pharmaceuticals | 120 |
| Foghorn Therapeutics | 106 |
| Scribe Therapeutics | 89 |
| Upstream Bio | 75 |
| Lexeo Therapeutics | 63 |
| Atea Pharmaceuticals | 55 |
CAPR News
- 1 day ago - Capricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
- 2 days ago - Capricor Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 2 days ago - Capricor Therapeutics Earnings release: Q2 2026 - Filings
- 2 days ago - Capricor Therapeutics Quarterly report: Q2 2026 - Filings
- 2 days ago - Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 days ago - Kaplan Fox Reminds Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery of the Lead Plaintiff Deadline on September 28, 2026 - Newsfile Corp
- 4 days ago - CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop - PRNewsWire
- 5 days ago - Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13 - GlobeNewsWire